ETH, DOGE, XRP Down 3% as Moody’s Downgrades U.S. Credit Rating
Major tokens slumped Saturday as investors digested the implications of Moody’s Ratings downgrading the U.S. credit score, with ether (ETH),…
Trex shares target cut by Benchmark, maintains Buy rating By Investing.com
A Benchmark analyst has adjusted the price target for Trex Company Inc (NYSE:), a leading manufacturer of wood-alternative decking products,…
Teladoc shares target cut, retains overweight rating on Q2 report By Investing.com
On Tuesday, Teladoc Health Inc. (NYSE:) experienced a significant adjustment in its stock price target. Piper Sandler has reduced the…
Analysts see bigger selloffs if Fitch cuts Kenya credit rating
A downgrade of Kenya’s credit rating by a second ratings agency could trigger a bigger market selloff by investors, analysts…
EQT Corp. shares hold as analyst backs Overweight rating citing FY24 outlook By Investing.com
On Thursday, Piper Sandler adjusted its price target for EQT Corp. (NYSE:EQT (ST:)) to $43.00, down from the previous $43.00,…
SAP shares price target raised, rating held on steady results By Investing.com
On Tuesday, BMO Capital Markets adjusted its outlook on shares of SAP SE (ETR:) (NYSE: SAP), increasing the stock's price…
Horror film fans go WILD over ‘psychologically scarring’ new movie – as it earns 100 per cent rating on Rotten Tomatoes
Horror movie fans have been sent into a frenzy over 'psychologically scarring' new flick - and it has already earned…
Worthington Steel stock maintains target, Overweight rating By Investing.com
On Friday, Worthington Steel Inc (NYSE:WS) retained its Overweight rating and $40.00 price target from KeyBanc, following the company's robust…
Moody’s cuts indebted oil firm Pemex’s rating by two notches to B3 By Reuters
© Reuters. FILE PHOTO: Signage of Petroleos Mexicanos (Pemex) is pictured at the company's headquarters in Mexico City, Mexico July…
Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts (NASDAQ:FDMT)
peterschreiber.media Goldman Sachs has reinstated its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT), citing upcoming catalysts. The investment bank said…
